h1

h2

h3

h4

h5
h6
TY  - JOUR
AU  - Barratt, Jonathan
AU  - Lafayette, Richard
AU  - Kristensen, Jens
AU  - Stone, Andrew
AU  - Cattran, Daniel
AU  - Flöge, Jürgen
AU  - Tesar, Vladimir
AU  - Trimarchi, Hernán
AU  - Zhang, Hong
AU  - Eren, Necmi
AU  - Paliege, Alexander
AU  - Rovin, Brad H.
TI  - Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy
JO  - Kidney international
VL  - 103
IS  - 2
SN  - 2157-1724
CY  - New York, NY
PB  - Elsevier
M1  - RWTH-CONV-250008
SP  - 391-402
PY  - 2022
N1  - Available online 19 October 2022
LB  - PUB:(DE-HGF)16
UR  - <Go to ISI:>//WOS:000922298000001
C6  - pmid:36270561
DO  - DOI:10.1016/j.kint.2022.09.017
UR  - https://publications.rwth-aachen.de/record/862041
ER  -